The ubiquity of "hepatic steatosis" and the growing mentions of "non-alcoholic fatty liver disease" (NAFLD) are impossible to ignore in the medical landscape. Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are on the global rise, mirroring the surge in obesity and metabolic risk factors. While it might be tempting to downplay the ... Continue Reading